Kohei Shitara: Biomarker Analysis of FLOT-Treated Gastric/GEJ Cancer
Kohei Shitara, Director of the Department of Gastrointestinal Oncology at National Cancer Center Hospital East, shared a post on X about a recent article by Amane Jubashi at al. published in JCO Precision Oncology:
“Please to share biomarker analysis of FLOT-treated gastric/GEJ cancer:
CLDN18.2 expression declined after FLOT but persisted in non-MPR cases — supporting its potential as a target in future perioperative or adjuvant trials.”
Title: Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors
Authors: Amane Jubashi, Izuma Nakayama, Naoya Sakamoto, Shogo Takei, Yuki Matsubara, Yu Miyashita, Seiya Sato, Shinpei Ushiyama, Akinori Kobayashi, Ukyo Okazaki, Dai Okemoto, Kazumasa Yamamoto, Saori Mishima, Daisuke Kotani, Akihito Kawazoe, Tadayoshi Hashimoto, Yoshiaki Nakamura, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Takayuki Yoshino, Takeshi Kuwata, Kazuma Sato, Takeo Fujita, Mitsumasa Yoshida, Masahiro Yura, Takahiro Kinoshita, Kohei Shitara
Read the Full Article on JCO Precision Oncology
More posts featuring Kohei Shitara.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023